Place de la chimiothérapie péri-opératoire

Surgery remains the cornerstone of treatment for resectable Non-Small Cell Lung Cancer (NSCLC). Complementary treatment, such as chemotherapy, is frequently indicated. Chemotherapy can be administered either before surgery (neo-adjuvant chemotherapy) or after surgery (adjuvant chemotherapy). Peri-operative chemotherapy was shown to improve overall survival, with a 5-year benefit of around 5% when compared to surgery alone. This occurs due to the elimination of micro-metastases, thus reducing the risk of recurrence. Future perspectives include the introduction of targeted therapies and personalized treatments in the peri-operative setting, similar to in advanced disease stages.